| 2021/3 |
2022/3 |
2023/3 |
2024/3 |
2025/3 |
|
|---|---|---|---|---|---|
| Cash flows from operating activities | 12,211 | 5,972 | 8,725 | 15,665 | 8,896 |
| Cash flows from investing activities | -5,174 | -5,888 | -6,478 | -8,056 | -8,611 |
| Cash flows from financing activities | -2,266 | -2,565 | 1,016 | -8,449 | -3,833 |
| Cash and cash equivalents at end of period | 12,278 | 10,520 | 14,696 | 14,653 | 11,927 |
| 2021/3 |
2022/3 |
2023/3 |
2024/3 |
2025/3 |
|
|---|---|---|---|---|---|
| Depreciation | 6,608 | 6,832 | 7,137 | 7,632 | 7,843 |
| Capital investment | 5,668 | 5,658 | 8,200 | 7,175 | 9,630 |
| Research and development expenses | 2,246 | 2,183 | 2,277 | 2,361 | 2,577 |